Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
Authors:
Open Access
- 3 June 2014
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 5 (1) , 255-265
Abstract
Introduction/aim Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of long-acting and short-acting insulin analogs. The primary objective of this study was to investigate the pharmacodynamic response of once-daily IDegAsp dosing in patients with type 1 diabetes. Pharmacokinetic response, as well as safety and tolerability, were assessed as secondary objectives. Methodology This was a single-center, open-label, single-arm study. Twenty-two subjects received once-daily insulin degludec (IDeg) (0.42 U/kg) for five consecutive days [with separate bolus insulin aspart (IAsp) as needed for safety and glycemic control], to achieve clinical steady state of the basal component. On Day 6, they received a single injection of IDegAsp (0.6 U/kg, comprising 0.42 U/kg IDeg and 0.18 U/kg IAsp). Pharmacodynamic response was assessed using a 30-h euglycemic glucose clamp, with blood glucose stabilized at a target of 5.5 mmol/L. Results The glucose infusion rate profile showed a rapid onset of action and a distinct peak due to IAsp, followed by a separate, flat and stable basal glucose-lowering effect due to the IDeg component. Modeling data suggested that the pharmacodynamic profile of IDegAsp was retained with twice-daily dosing (allowing for coverage of two main meals daily). IDegAsp was well tolerated and no safety issues were identified in this trial. Conclusions In conclusion, the IAsp component of IDegAsp has a fast onset of appearance and a peak covering the prandial phase, while the IDeg component has a flat and an evenly distributed pharmacokinetic profile over 24 h. IDegAsp is the first co-formulation of a basal insulin analog with an ultra-long duration of action and a mealtime insulin analog in a single soluble injection. These properties translate into clinically relevant benefits, including improved glycemic control and reduction in hypoglycemia.Keywords
This publication has 24 references indexed in Scilit:
- Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal InsulinPharmaceutical Research, 2012
- The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir InsulinDiabetes Care, 2012
- Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetic Medicine, 2012
- THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesEuropean Journal of Endocrinology, 2012
- Standards of Medical Care in Diabetes—2012Diabetes Care, 2011
- Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 DiabetesDiabetes Care, 2011
- Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficientDiabetes, Obesity and Metabolism, 2009
- Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trialDiabetes, Obesity and Metabolism, 2008
- Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28AspDiabetic Medicine, 1993